Assessment of scientific substantiation of health claims on foods in the EU

Albert Flynn

University College, Cork Ireland

EFSA@10: Challenging Boundaries in Risk Assessment – Sharing Experiences, 7-8 November, 2012, Parma, Italy

Outline

- EU Regulation on nutrition and health claims the need for substantiation
- EFSA review of the evidence for scientific substantiation of health claims
- Health claims with a favourable evaluation by EFSA
- Issues arising with review of evidence on health claims by EFSA
- EFSA guidance for applicants for health claims
- Future perspectives

EU Regulation 1924/2006 on Nutrition and Health Claims made on foods:

the requirement for scientific substantiation of health claims

EU Regulation 1924/2006: scientific substantiation

- Scientific substantiation should be the main aspect to be taken into account for the use of health claims and <u>food</u> <u>business operators</u> using claims should justify them
- Health claims should only be authorized for use in the Community after a <u>scientific assessment of the highest</u> <u>possible standard</u>
- In order to ensure harmonized scientific assessment of these claims, the <u>European Food Safety Authority</u> should carry out such assessments - <u>independent review</u>

EU evidence standard for health claims

- All claims must be substantiated by <u>generally accepted</u> scientific evidence, taking into account totality of available scientific data, and weighing the evidence
 - = generally accepted by scientific experts

•whether the evidence for a claim meets this standard is a scientific judgement of EFSA's NDA Panel

EFSA review of the evidence submitted for scientific substantiation of health claims


EFSA's role in assessment of health claims

- EFSA's **NDA panel** performs **independent assessment** of claims and provides scientific advice on substantiation
- 20 Panel experts
- Supported by Working Group, EFSA staff and additional experts (as needed)

Authorisation of claims is by EU Commission (+ EU Member States + Eur. Parliament scrutiny)

Main issues addressed by NDA Panel

- 1. is the food/constituent defined and characterised?
- 2. is the claimed effect defined and is it a beneficial physiological effect?
- 3. is a **cause and effect relationship** established between the consumption of the food/constituent and the claimed effect?
- for the target group
- under the proposed conditions of use



Evidence review - steps

- 1. Selection of relevant human studies (central studies)
- 2. Review of individual human studies
- 3. Review of studies on biological plausibility mechanisms, bioavailability
- 4. Weighing the evidence combining the relevant human studies + other studies to conclude on substantiation

- transparent scientific judgement of the NDA Panel
- published scientific opinion in EFSA journal:

http://www.efsa.europa.eu/en/publications/efsajournal.htm

Relevant human studies

- studies carried out with the food/constituent for claim
- appropriate outcome measure(s) for the claimed effect
- conditions for studies comparable to conditions of use for claim (e.g. quantity of food/constituent)
- study groups representative of the target group or extrapolation to the target population possible

Review of relevant human studies

- Published and unpublished studies accepted
- Review by study type e.g. intervention, observational
- Study quality design, execution, analysis, reporting
- Additional information may be requested from the applicant
- Studies of low quality may be excluded

Weighing the evidence

- combine the relevant human studies by study type (RCT strongest evidence)
 - number of studies for and against, taking into account study population, study quality, study size, effect size, dose-response
 - consistency among studies
- evidence for biological plausibility bioavailability, mechanisms
 - studies in humans, animals, in vitro

Health Claims with a favourable evaluation by EFSA

Examples

Claims for development and health of children (11)

Claim	Food/constituent
Brain development + eye development in foetus, infant	DHA (maternal)
Visual development in infant	DHA (infant)
Growth & development of children	ALA, LA
Cognitive development	Iron

Iron and cognitive development

Authorized claim:

Iron contributes to normal cognitive development of children

EFSA:

Based on evidence of the biochemical functions of iron in the brain and effects of iron deficiency on cognitive function in children

Conditions of use:

The claim may be used only for food which is at least a source of iron (≥15% RDA per 100g)

Disease risk reduction claims (11)

Claim	Food/constituent
Blood LDL-cholesterol/heart	Plant sterols/stanols
disease	oat β-glucans
	MUFA/PUFA replacing saturated fat
Dental plaque/caries	Sugar-free chewing gum
Plaque acids/caries	
Demineralisation/caries	
Bone density/osteoporotiic	Ca;
fracture	Ca + vitamin D
Falling/osteoporotic fracture	
	Vitamin D

Plant sterols/plant stanol esters and coronary heart disease

Authorized claim:

Plant sterols and plant stanol esters have been shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the development of coronary heart disease.

EFSA:

Claim substantiated based on 41 human studies (sterols) and 30 human studies (stanol esters)

Conditions of use: Information to the consumer that the beneficial effect is obtained with a daily intake of 1.5-2.4 g plant sterols/stanols

Function claims (>200)

Claim	Food/constituent
Tooth mineralisation	Sugar replacers, fluoride
Bone	calcium, vit. D, vit. K
Body weight	Meal replacements, VLCD
Bowel function	Cereal fibres (various)
Blood glucose after meals	Pectins, guar gum, resistant starch, sugar replacers
Blood pressure	potassium, reduced sodium
Blood LDL-cholesterol	Pectins, β-glucans, MUFA, PUFA, reduced sat. fat
Platelet aggregation	Water sol. tomato conc.

Nutrient function claim: calcium and bone

Authorized claim:

Calcium is needed for the maintenance of normal bones

EFSA:

Based on generally accepted function of calcium in bone

Conditions of use: The claim may be used only for food which is at least a source of calcium (≥15% RDA per 100g)

Water soluble tomato concentrate (WSTC) and blood flow

Authorized claim:

Water-Soluble Tomato Concentrate helps maintain normal platelet aggregation, which contributes to healthy blood flow

EFSA:

claim substantiated based on eight human studies and seven non-human studies

(including 10 studies claimed as proprietary: 7 unpublished studies protected)

EU register of health claims

- EU Register of nutrition and health claims made on foods
- Authorised health claims (241)
- Non-authorised health claims (1796)

http://ec.europa.eu/nuhclaims/index.cfm?event=register.home

Issues arising with review of evidence on health claims by EFSA

Examples

Quality of human studies

Commonly observed sources of bias

Intervention studies

- design insufficient size, control of confounding
- execution randomisation, blinding
- statistical analysis drop outs and treatment of missing data, treatment of multiple outcomes

Observational studies

measurement of relevant exposure, confounding

Evidence from studies in patients

- Health claims are for general population, not treatment of patients (medicinal)
- Some diseased populations may be considered representative of (non-diseased) target groups when mechanisms for effect are the same in both groups

- Type II diabetics (treated with diet only) for claims on post-prandial blood glucose
 - But not if treated with drugs for lowering blood glucose

Claims on probiotics/prebiotics

Non-authorised claim:

Helps to maintain a desirable balance of beneficial bacteria in the digestive system

- •EFSA does not consider that increasing numbers of lactobacilli/bifidobacteria in the intestine is a beneficial physiological effect *per se*
- Beneficial consequences should be demonstrated
 - lactose digestion (claim authorised)
 - defence against pathogens in the intestine (no claim substantiated to date)

EFSA Guidance for Applicants for Health Claims

EFSA Guidance for Substantiation of Health Claims on Foods in EU

- General guidance principles for scientific substantiation of health claims
- Specific guidance on scientific requirements for specific types of health claims
- >400 scientific opinions, technical reports

http://www.efsa.europa.eu/en/nda/ndaclaims.htm

EFSA guidance on scientific requirements for specific types of claims

- which relationships are eligible for health claims
- what types of studies, outcome measures and study groups are appropriate:
 - Gut, immune
 - Bone, joints, skin, oral
 - Appetite, body weight, blood glucose
 - Antioxidants, cardiovascular
 - Physical performance
 - Neurological, psychological

http://www.efsa.europa.eu/en/nda/ndaclaims.htm

Future perspectives

- EFSA has defined scientific criteria for substantiation of health claims and has provided extensive guidance to applicants
 - will help set future directions for research and will guide innovation

 International collaboration between scientific authorities on approaches to scientific substantiation of health claims